OrbiMed-affiliated fund OPI VII reports 12.3% stake in Aspen Neuroscience
A Schedule 13D filed on 6 November 2026 shows OPI VII, a Delaware limited partnership managed by OrbiMed Advisors LLC, holds 3,589,132 shares of Aspen Neuroscience, Inc., equal to approximately 12.3% of the company's outstanding shares.
Written and published automatically by the Loro Intelligence Engine from public records. No editor reviewed this before publication.
A Schedule 13D filed with the SEC on 6 November 2026 shows that OPI VII, a Delaware limited partnership managed by OrbiMed Advisors LLC and its general partner OrbiMed GP, holds 3,589,132 shares of Aspen Neuroscience, Inc., approximately 12.3% of the company's outstanding shares, and that OrbiMed Advisors member Peter A. Thompson sits on the company's board of directors.
- Shares held by OPI VII
- 3,589,132
- Percentage of outstanding shares
- approximately 12.3%
- Filing date
- 6 November 2026
- Investors' Rights Agreement date
- 1 October 2025
- Board member tied to OrbiMed
- Peter A. Thompson
OrbiMed Advisors LLC filed a Schedule 13D with the SEC on 6 November 2026 disclosing that OPI VII, a Delaware limited partnership, holds 3,589,132 shares of Aspen Neuroscience, Inc., representing approximately 12.3% of the company's issued and outstanding shares as of the filing date.
The filing states that OrbiMed GP serves as general partner of OPI VII and that OrbiMed Advisors is the managing member of OrbiMed GP, giving both entities shared power to direct the vote and disposition of the shares held by OPI VII. OrbiMed Advisors exercises this authority through a management committee comprising Carl L. Gordon, W. Carter Neild and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII, according to the filing.
The Schedule 13D states that Peter A. Thompson, a member of OrbiMed Advisors, sits on Aspen Neuroscience's board of directors, and that as a result OrbiMed Advisors and OrbiMed GP may have the ability to affect and influence control of the company. The filing also states that Thompson is obligated under an agreement with OrbiMed Advisors to transfer any stock options or equity awards he receives as a director, or their economic benefit, to OrbiMed Advisors, which in turn provides them to OPI VII.
The filing discloses that OPI VII and other stockholders entered into an Amended and Restated Investors' Rights Agreement with the company dated 1 October 2025, which the filing says grants certain holders of shares, including those issuable on conversion of preferred stock, demand, piggyback and Form S-3 registration rights following the company's initial public offering, subject to conditions set out in the agreement including the right of the board to delay registration if it determines in good faith that it would be materially detrimental to the company and its stockholders.
The filing does not state whether OrbiMed Advisors or OPI VII intend to acquire additional shares or to seek any specific changes at the company beyond the board representation and registration rights described.
Primary sources
1 recordEvery factual claim above is drawn from these records. Each link resolves to the publisher’s own copy.